Journal article
Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S).
Abstract
248
Background: The SHARP and Asia Pacific (AP) trials showed that S improves OS compared to placebo in advanced HCC. However, OS was worse in the AP trial which included predominantly Asian patients. It is unclear if ethnicity, or perhaps Hepatitis B (HBV) infection, is a poor prognostic factor for these patients. The purpose of this study was to determine whether ethnicity affects OS in patients with advanced HCC being …
Authors
Meyers DE; Lee-Ying RM; Alghamdi MA; Cheung WY; Samawi H; Tam VC
Journal
Journal of Clinical Oncology, Vol. 36, No. 4_suppl, pp. 248–248
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 1, 2018
DOI
10.1200/jco.2018.36.4_suppl.248
ISSN
0732-183X